Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01981473 · ClinicalTrials.gov registry record
Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 605
- Enrollment target
NCT01981473 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 605 participants.
The verdict
NCT01981473 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 605 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the relationship between anti-drug antibodies, serum drug concentrations, and clinical response for rheumatoid arthritis patients being treated with etanercept, adalimumab or infliximab.
Interventions
- OTHER no intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 605 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01981473
The ClinicalTrials.gov registry entry for NCT01981473 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 605 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which no intervention is the first listed.
NCT01981473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01981473 about?
NCT01981473 is a clinical study titled "Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab". The purpose of this study is to examine the relationship between anti-drug antibodies, serum drug concentrations, and clinical response for rheumatoid arthritis patients being treated with etanercept, adalimumab or infliximab.
What is the current status of trial NCT01981473?
This trial is currently completed. The enrollment target is 605 participants. The study started on 2014-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01981473?
The interventions under investigation include: no intervention (OTHER).
Who is sponsoring clinical trial NCT01981473?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.